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Abstract
Introduction: MicroRNAs (miRNAs) are a class of small non-coding RNAs (20 to 24 nucleotides) that post-
transcriptionally modulate gene expression. A key oncomir in carcinogenesis is miR-21, which is consistently
up-regulated in a wide range of cancers. However, few functional studies are available for miR-21, and few targets
have been identified. In this study, we explored the role of miR-21 in human breast cancer cells and tissues, and
searched for miR-21 targets.
Methods: We used in vitro and in vivo assays to explore the role of miR-21 in the malignant progression of human
breast cancer, using miR-21 knockdown. Using LNA silencing combined to microarray technology and target
prediction, we screened for potential targets of miR-21 and validated direct targets by using luciferase reporter
assay and Western blot. Two candidate target genes (EIF4A2 and ANKRD46) were selected for analysis of
correlation with clinicopathological characteristics and prognosis using immunohistochemistry on cancer tissue
microrrays.
Results: Anti-miR-21 inhibited growth and migration of MCF-7 and MDA-MB-231 cells in vitro, and tumor growth
in nude mice. Knockdown of miR-21 significantly increased the expression of ANKRD46 at both mRNA and protein
levels. Luciferase assays using a reporter carrying a putative target site in the 3’ untranslated region of ANKRD46
revealed that miR-21 directly targeted ANKRD46. miR-21 and EIF4A2 protein were inversely expressed in breast
cancers (rs = -0.283, P = 0.005, Spearman’s correlation analysis).
Conclusions: Knockdown of miR-21 in MCF-7 and MDA-MB-231 cells inhibits in vitro and in vivo growth as well as
in vitro migration. ANKRD46 is newly identified as a direct target of miR-21 in BC. These results suggest that
inhibitory strategies against miR-21 using peptide nucleic acids (PNAs)-antimiR-21 may provide potential
therapeutic applications in breast cancer treatment.
Introduction
Breast cancer (BC) is by far the most frequent cancer of
women (23% of all cancers), with an estimated 1.15 mil-
lion new cases worldwide in 2002 [1]. It is still the lead-
ing cause of cancer mortality in women [1]. Despite
research and resources dedicated to elucidating the
molecular mechanisms of BC, the precise mechanisms
of its initiation and progression remain unclear.
MicroRNAs (miRNAs) are small non-coding RNAs
(20 to 24 nucleotides) that post-transcriptionally modu-
late gene expression by negatively regulating the stability
or translational efficiency of their target mRNAs [2].
After the discovery of miRNAs, and findings indicating
that they play a role in cancer, the concept of “onco-
mirs” was proposed [3]. In particular, miR-21 [miRBase:
MIMAT0000076] has emerged as a key oncomir, since
it is the most consistently up-regulated miRNA in a
wide range of cancers [4-7].
Functional studies showed that knockdown of miR-21
in MCF7 cells led to reduced proliferation and tumor
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cells significantly reduced invasion and lung metastasis
[10]. These data clearly implicate miR-21 as a key mole-
cule in carcinogenesis, but functional studies that
demonstrate cause and effect relationships between
miR-21 and target genes are lacking. Given that miRNAs
usually target multiple genes post-transcriptionally, miR-
21 is likely to exert its effects by regulating many genes
involved in BC.
The inhibition of miRNAs using antisense oligonu-
cleotides (ASOs) is a unique and effective technique for
investigating miRNA functions and targets. Peptide
nucleic acids (PNAs) are artificial oligonucleotides con-
structed on a peptide-like backbone. PNAs have a stron-
ger affinity and greater specificity for DNA or RNA than
natural nucleic acids, and are resistant to nucleases [11].
PNA-based ASOs can be used without transfection
reagents, and are highly effective and sequence-specific.
They provide long-lasting inhibition of miRNAs, and
show no cytotoxicity up to 1 μM [11]. Therefore, we
used a PNA miR-21 inhibitor for in vivo investigation.
In this study, we explored the role of miR-21 in the
malignant progression of human BC by assaying in vitro
and in vivo function after miR-21 knockdown. We also
searched for miR-21 targets using gene prediction-based
and systematic screening approaches. Two potential tar-
get genes eukaryotic translation initiation factor 4A2
(EIF4A2) [NCBI: NM001967] and ankyrin repeat
domain 46 (ANKRD46) [NCBI: NM198401] were
selected for correlation analysis between protein levels
and clinicopathological characteristics as well as prog-
nosis using immunohistochemistry (IHC) on cancer tis-
sue microrrays (TMAs).
Materials and methods
Tissue specimens and TMAs construction
In situ hybridization analysis was performed on fresh
samples from BC or fibroadenoma (FA) tissues with
paired normal adjacent tissues (NATs, > 2 cm from
tumor tissues) obtained from Sun Yat-sen University
Cancer Center (SYSUCC) (Guangzhou, China) between
January and March 2009. For IHC staining of miR-21
predicted target genes, formalin-fixed paraffin-embedded
tissues were obtained from 99 randomly selected BC
patients without neoadjuvant therapy at SYSUCC from
January 2000 to November 2004, from whom informed
consent and agreement, and clinicopathological informa-
tion was available. A pathologist reviewed slides from all
blocks, selecting representative areas of invasive tumor
tissue to be cored. Selected cores were analyzed in
duplicate using a MiniCore Tissue Arrayer (Alphelys,
Passage Paul Langevin, Plaisir, France) with a 1-mm
needle. The diagnosis and histological grade of each
case were independently confirmed by two pathologists
based on World Health Organization classification [12].
The clinical stage was classified according to the Ameri-
can Joint Committee on Cancer (AJCC) tumor-lymph
node-metastasis (TNM) classification system [13]. The
study was approved by the Research Ethics Committee
of SYSUCC (Reference number: YP-2009168). The clini-
copathological characteristics and follow-up data of the
patients are summarized in Table 1.
Locked nucleic acid (LNA)-based in situ hybridization for
miRNA
To study the spatial and temporal expression of miR-
NAs with high sensitivity and resolution, the miRNA
chromogenic in situ hybridization (CISH) and fluores-
cein in situ hybridization (FISH) protocol [14] were
optimized (Additional file 1).
Transfection of LNA-antimiR-21 into BC cells
MCF-7 and MDA-MB-231 cells were maintained in
Dulbecco’s modified Eagle’s medium, supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin and 10%
fetal bovine serum (GIBCO-Invitrogen, Carlsbad, CA,
USA). For transfection, the LNA-antimiR-21 or LNA-
control (Exiqon A/S, Skelstedet, Vedbaek, Denmark)
Table 1 Clinicopathological characteristics and follow-up
data for 99 patients with BC
Characteristics Number of patients/Number
analyzed (%)
Median age (range) 48 (30 to 74) (years)
Histological type*
Ductal 93/99 (94%)
Lobular 1/99 (1%)
Other 5/99 (5%)
Histological grade*
I 22/99 (22%)
II 58/99 (58%)
III 19/99 (20%)
Lymph node status at time of primary diagnosis
Metastasis 57/99 (58%)
No metastasis 42/99 (42%)
AJCC clinical stage**
I 8/99 (8%)
II 68/99 (69%)
III 23/99 (23%)
Overall survival (median, range) 74 (6 to 112) (months)
Alive without evidence of
cancer
45/99 (68%)
Alive with cancer 14/99 (14%)
Died of cancer 40/99 (40%)
Died of other disease 0/99 (0%)
* According to the WHO classification of BC. ** According to the AJCC staging
system; AJCC, American Joint Committee on Cancer; BC, breast cancer; WHO,
World Health Organization.
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Lipofectamine 2000 reagent (Invitrogen).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay and colony formation assay
Growing cells (2 × 10
3 cells per well) were seeded into
96-well plates. At 24 h after LNA-transfection, cells
were stained with 20 μl sterile MTT dye (5 mg/ml;
S i g m a - A l d r i c hC o r p ,S t .L o u i s ,M O ,U S A ) ,f o l l o w e db y
4 h at 37°C. After supernatant removal, 150 μlo f
dimethyl sulphoxide (Sigma) was added and thoroughly
mixed for 15 minutes. Absorbence was measured with a
microplate reader (SpectraMax M5; Molecular Devices
Corp., Silicon Valley, CA, USA) at 490 nm. For colony
formation assays, cells were seeded in six-well plates
(0.5 × 10
3 cells per well) and cultured for two weeks.
Colonies were fixed with methanol for 10 minutes and
stained with 1% crystal violet (Sigma) for 1 minute.
Each cell group was measured in triplicate.
Wound healing assay
Cells cultured in the presence of 50 nM LNA-antimiR-
21 or LNA-control for 24 h were allowed to reach
confluence before dragging a 1-mL sterile pipette tip
(Axygen Scientific, Inc., Union City, CA, USA) through
the monolayer. Cells were washed to remove cellular
debris and allowed to migrate for 24 h or 48 h. Images
were taken at time 0 h, 24 h and 48 h post-wounding
using a digital camera system (Leica DFC 480; Leica
Microsystems, Bannockburn, IL, USA). The motility of
the cells was determined as repaired area percentage
[15]. Each cell group was measured in triplicate.
Validation of tumor growth-promoting activity of miR-21
in an animal model
Five- to six-week-old female BALB/c-nude mice (Slaccas
Shanghai Laboratory Animal Co., Ltd., Shanghai, China)
were used for experimental tumorigenicity assays. To
facilitate estrogen-dependent xenograft establishment,
each mouse received 17-estradiol (20 mg/kg; Sigma)
intraperitoneally once a week. One week after treatment,
equivalent amounts of MCF-7 cells, treated with PNA-
antimiR-21 or PNA-control (100 nM for 48 h; Panagene,
Inc., Yuseong-gu, Daejeon, Korea) without transfection
reagents according to the manufacturer’sp r o t o c o l ,w e r e
injected subcutaneously (10
7 cells/tumor) into the left
axilla of nude mice [16]. Mice were weighed, and tumor
width (W) and length (L) were measured every day.
Tumor volume was estimated according to the standard
formula: V = ∏/6 × L × W
2, as described previously
[17]. Animals were killed nine days after initial growth
of the MCF-7 xenografts was detectable, and tumors
were extracted. In all experiments, the ethics guidelines
for investigations in conscious animals were followed,
with approval from the local Ethics Committee for Ani-
mal Research.
mRNA array and data mining
MCF-7 and MDA-MB-231 cells were transfected either
with LNA-antimiR-21 or with LNA-control at a final
concentration of 50 nM. Total RNAs were isolated from
MCF-7 cells 48 h post transfection and from MDA-MB-
231 cells 36 h post transfection, respectively, using Tri-
zol Reagent (Invitrogen). The mRNA expression profile
was performed using human genome oligo array service
V1.0 (Catalog Number 400010; CapitalBio, Beijing,
China) as described [18]. Each sample was analyzed
once, and the CapitalBio data preprocess, normalization
and filtering were as previously described [18]. Ratios
were defined as marginal signal intensity when there
was a substantial amount of variation in the signal
intensity within the pixels from 800 to 1,500. All
t h em i c r o a r r a yd a t ah a v eb e e nd e p o s i t e dt ot h e
Gene Expression Omnibus (GEO) [19] and are accessi-
ble through GEO Series accession number [GEO:
GSE20627].
Relative quantitative reverse transcription-polymerase
chain reaction (qRT-PCR)
For validation of mRNA array and quantitative analysis
of miR-21 as well as potential target genes, qRT-PCR
w a su s e da sp r e v i o u s l yd e s c r ibed [20]. The primers for
qRT-PCR are in Additional file 2. The relative expres-
sion was calculated using the equation relative quantifi-
cation (RQ) = 2
-ΔΔ
CT [21].
Computational prediction of miR-21 target genes
Predicted miR-21 targets were identified using the algo-
rithms of TargetScan 5.1 [22], miRBase Targets V5 [23],
miRNAMap 2.0 [24], PicTar [25] and miRanda 3.0 [26].
Luciferase reporter assay
The 3’ untranslated region (3’ UTR) of mRNA sequence
of ANKRD46 containing predicted miR-21 binding site
was amplified by PCR. PCR primers were listed in Addi-
tional file 2. After amplification, PCR products were
cloned into the pMIR-REPORT (Applied Biosystems,
Foster City, CA, USA), resulting in the pMIR-REPORT-
3’ANKRD46.M u t a t i o no fANKRD46 was introduced in
the predicted miR-21 binding site by a QuikChange site-
directed mutagenesis kit (Stratagene, Foster City, CA,
USA). Wild-type EIF4A2 and mutant EIF4A2 were
cloned into pMD19-T Simple Vector by TaKaRa Bio-
technology CO., LTD. (Dalian, Liaoning, China) and
then were individually subcloned downstream of the
luciferase coding sequence in the pMIR-REPORT
(Applied Biosystems). All constructs were verified by
DNA sequencing.
Yan et al. Breast Cancer Research 2011, 13:R2
http://breast-cancer-research.com/content/13/1/R2
Page 3 of 14For reporter assays, wide-type or mutant reporter con-
structs (15 ng) were cotransfected into 293T cells in
twelve-well plates with miR-21 or miR-control (50 nM;
GenePharma, Shanghai, China) and Renilla plasmid
(5 ng) using lipofectamine 2000 (Invitrogen). Firefly and
Renilla luciferase activities were measured by using a
Dual Luciferase Assay (Promega, Madison, WI, USA)
24 h after transfection. Firefly luciferase values were
normalized to Renilla, and the ratio of firefly/renilla was
presented.
Immunoblot analysis
Cells were harvested and lysed in radioimmune precipi-
tation buffer (Upstate, Lake Placid, NY, USA) at the
indicted time post-transfection. Antibodies used for
immunoblot analysis were against ANKRD46 (1:500
dilution; sc-87548, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), EIF4A2 (1:1000 dilution; ab31218,
Abcam, Cambridge, UK) and GAPDH (1:3,000 dilution;
sc-32233, Santa Cruz Biotechnology), as a loading con-
trol. All bands were detected using a SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Rockford,
IL, USA).
Immunohistochemical staining
IHC and scoring of the estrogen receptor (ER), proges-
terone receptor (PR) and CerbB2 were performed as
previously described [20]. Slides were incubated with
primary antibodies against ANKRD46 (1:150 dilution;
sc-87548, Santa Cruz Biotechnology); or EIF4A2 (1:700
dilution; ab31218, Abcam). All slides were processed
simultaneously in identical conditions per the manufac-
turer’s instructions. Three observers independently
determined consensus scoring of EIF4A2 and ANKRD46
immunostaining using a semi-quantitative estimation
according to the percentage of positive cells and the
intensity of staining as described previously [27]. With
these data, the composite score was obtained by adding
the values of the staining intensity and relative abun-
dance [28]. Samples with scores lower than the median
score were grouped as low protein expression [29].
Statistical analysis
Spearman’s rank correlation test was used for correla-
tion analysis between predicted target gene protein
levels and endogenous miR-21 levels measured pre-
v i o u s l yb yq R T - P C R[ 2 0 ] .P e a r s o n ’sC h i - S q u a r et e s t s
were used to compare target gene expression levels to
clinicopathological characteristics. Survival curves were
estimated by the Kaplan-Meier method and log-rank
test. All analysis used SPSS 16.0 for Windows (SPSS Inc,
Chicago, IL, USA). All tests were two-tailed, and the sig-
nificance level was set at P < 0.05.
Results
miR-21 is overexpressed in BC tissues and cell lines
Expression of miR-21 was detected in the cytoplasm in
cancerous and luminal epithelial cells, and occasionally
in fibroblasts. In BC patients, an increase in miR-21
staining intensity was observed in BC and FA tissues
compared with corresponding NATs (Figure 1a). Parallel
detection by FISH is shown in Additional file 3. Consis-
tent with the CISH results, quantitative analysis indi-
cated that miR-21 expression was significantly increased
by 4.44- to 2.02-fold in BC tissues compared with NATs
(P = 0.019, n = 4), and increased in FA tissues by 3.03-
to 1.89-fold (P = 0.008, n =4 ,F i g u r e1 b ) .F I S Ha n d
qRT-PCR were used to measure miR-21 levels in five
BC cell lines (MCF-7, MDA-MB-231, MDA-MB-453,
MDA-MB-435, and SK-BR-3) and one non-tumorigenic
epithelial cell line (MCF-10A). Consistent with previous
findings [8,10,30], miR-21 overexpressed in MCF-7,
MDA-MB-231 and MDA-MB-453 cell lines from 6.48-
to 4.04-fold compared with MCF-10A cell line (P <
0.01, Figure 1d).
LNA-antimiR-21 inhibits BC cell growth, proliferation and
migration in vitro
MCF-7 and MDA-MB-231 cell lines were selected to
investigate miR-21 functions and targets by using
sequence-specific functional inhibition of miR-21,
because both cell lines express higher levels of miR-21
compared with MCF-10A cells. Optimal doses and time
points for transfection of LNA reagents were deter-
mined by evaluating miR-21 levels using qRT-PCR
(Additional file 4). Knockdown of miR-21 reduced miR-
21 levels by 98% in MCF-7 cells, and 77% in MDA-MB-
231 cells (P < 0.01) (Figure 2a). LNA-antimiR-21 led to
a decrease in MCF-7 cell growth (Figure 2b) and prolif-
eration (29%, P = 0.003, Figure 2c). Similar inhibition of
cell growth and proliferation effects (51%, P =0 . 0 1 1 ,
Figure 2c) was also observed in MDA/LNA-antimiR-21
cells (data not shown). In vitro wound healing assays
showed that wound repair in MCF/LNA-antimiR-21 and
MDA/LNA-antimiR-21 was delayed compared with
MCF/LNA-control and MDA/LNA-control cells (data
not shown). Knockdown of miR-21 suppressed MCF-7
cell migration by up to 69% (P = 0.013), and MDA-MB-
231 migration by 51% (P = 0.001), compared with the
LNA-control at 24 h after wound scratch (Figure 2d).
These data demonstrate the tumorigenic properties of
miR-21 in regulating cell growth, proliferation and
migration.
PNA-antimiR-21 inhibits tumor growth in vivo
To address the potential effects of PNA-antimiR-21 in
vivo on the growth of BC cells, equal numbers (3 × 10
7)
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Page 4 of 14Figure 1 Altered expression of miR-21 in different breast tumor types and breast cell lines. (a) CISH detection using miR-21 LNA
detection probe (blue) or scramble-miR as negative control were performed on consecutive 8 μM cryo-sections obtained from BC/FA tissues
and corresponding NATs. DNA was counterstained with methyl green (green, × 400 magnification). (b) Total RNA was used to quantify miR-21
expression by relative qRT-PCR, normalizing on U6 RNA levels. The graph shows a log2-scale RQ calculated by normalizing the miR-21 expression
values in the tumors on those in the NATs. Data indicate the mean (+SD) of four independent samples. * P < 0.05. (c) FISH detection of miR-21
in five BC cell lines (MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-435, SK-BR-3) and one non-tumorigenic epithelial cell line (MCF-10A). Positive in
situ hybridization signals are visualized in green, while blue depicts DAPI nuclear stain (× 1,000 magnification). (d) qRT-PCR analysis show that
MCF-7, MDA-MB-231 and MDA-MB-453 cells express higher levels of miR-21 compared with MCF-10A cells. Data are mean (+SD) of three
replicates. ** P < 0.01; BC, breast cancer; FA, fibroadenoma; NATs, normal adjacent tissues.
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Page 5 of 14of MCF-7 cells treated with PNA-antimiR-21 or the
PNA-control were subcutaneously injected into female
nude mice (eight animals per treatment). As seen in Fig-
ure 3b and 3c, detectable tumor masses (0.011 ± 0.013
g, mean ± standard deviation, SD) were seen in only 5/8
(62.5%) of mice in the MCF/PNA-antimiR-21 group,
while much larger tumors (0.036 ± 0.038 g, mean ± SD)
were detected in all mice in the MCF/PNA-control
group (P = 0.065, Mann-Whitney test). Both tumor
weight and number showed that MCF/PNA-control
cells formed larger tumors more rapidly (Figure 3a, c)
than MCF/PNA-antimiR-21 cells in nude mice. PNA-
antimiR-21 reduced miR-21 expression by 5.72 log2-
scale in MCF-7 cells 48 h post-treatment compared
with that in the control (P < 0.01). miR-21 expression in
xenograft tumors of PNA-antimiR-21 group was 0.96
log2-scale higher than that of the control group (P <
0.05; Figure 3e). Notably, MCF/PNA-antimiR-21 tumor
cells were decreased in mitotic and pathological mitotic
stages compared with MCF/PNA-control cells, indicat-
ing a decreased in cell proliferative activity and apopto-
sis (Figure 3d).
Identification of potential miR-21 targets
It is known that animal miRNAs regulate gene expres-
sion by inhibiting translation and/or by inducing degra-
dation of target. In our study, most modulated genes in
the mRNA differential expression profiles changed by
less than two-fold. Since mRNA levels regulated by less
than two-fold may still be miRNA targets, we defined
differentially expressed genes as no less than 1.3-fold
change [31]. Comparative analysis of LNA-antimiR-21
Figure 2 LNA-antimiR-21 suppressed BC cell growth, proliferation and migration in vitro. (a) miR-21 expression levels (normalized to U6
RNA) were significantly depressed by 98% (P < 0.01) in MCF-7/LNA-antimiR-21 and 77% (P < 0.01) in MDA/LNA-antimiR-21 cells, relative to the
LNA-control. The graph shows RQ calculated by normalizing the miR-21 expression values in LNA-antimiR-21 treated cells on those in the LNA-
control treated cells. (b) MTT assay showed that MCF-7/antimiR-21 and MDA-MB-231/antimiR-21 cells grew slower than cells transfected with the
LNA-control. (c) Representative wells showing total numbers of colonies formed by LNA-antimiR-treated cells standardized against control cells
(set to 100%). (d) Representative image of in vitro wound healing assay of MCF-7 and MDA-MB-231 at 0, 24 and 48 h after wound scratch. Data
are mean + SD, n =3 .*P < 0.05, ** P < 0.01.
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regulation of 394 genes in MCF/LNA-antimiR-21, of
which 228 (58%) were up-regulated and 166 (42%) were
down-regulated. 321 genes were differentially expressed
in MDA/LNA-antimiR-21 cells, of which 190 (59%)
were up-regulated, and 131 (41%) down-regulated
(Figure 4a). The intersection of MCF/LNA-antimiR-21
and MDA/LNA-antimiR-21 consisted of 27 genes (18
up- and 9 down-regulated; Figure 4b and Table 2).
To further screen potential direct targets, we com-
pared the 27 candidate mRNAs with miR-21 targets
predicted by TargetScan 5.1, miRBase Targets V.5,
Figure 3 Effect of miR-21-knockdown on MCF-7 cells growth in nude mice: in vivo functional studies. MCF-7 cells (10
7 cells/tumor),
treated with PNA-antimiR-21 or PNA-control (100 nM for 48 h) without transfection reagents, were injected subcutaneously into the left axilla of
nude mice. (a) Growth curves for MCF/PNA-antimiR-21 (n = 5) vs. MCF/PNA-control (n = 8) cells in an in vivo proliferation assay. All P-values >
0.05. (b) Tumors were weighed after animals were killed at 17 days post-tumor-cell injection. Decreasing trend for both number and size of
tumors from MCF/PNA-antimiR-21 compared with MCF/PNA-control group, although differences were not significant (P = 0.065, Mann-Whitney
test). (c) Mice and tumors extracted from MCF/PNA-antimiR-21 and MCF/PNA-control groups. (d) Representative photomicrographs of CISH for
miR-21 on xenograft tumor sections obtained from mice bearing MCF/PNA-antimiR-21 or MCF/PNA-control groups (× 400). (e) qRT-PCR analysis
of miR-21 expression in MCF-7 cells 48 h post PNA-treatment and in xenograft tumors after mice sacrifice. Data in (a), (b) and (e) indicate the
mean + SD. * P < 0.05, ** P < 0.01. PNA, peptide nucleic acid.
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mRNAs, 3 were recognized by the algorithms (Table 2).
Because miR-21 targets are expected to up-regulated for
the LNA-antimiR-21 samples, ANKRD46 and EIF4A2,
the two up-regulated genes upon miR-21 knockdown in
the two cell lines and predicted by target prediction pro-
grams, were selected for further investigation.
miR-21 directly targets ANKRD46 in BC cells
The microarrays were validated by qRT-PCR assay.
Consistent with the microarray results, qRT-PCR
showed increased ANKRD46 and EIF4A2 mRNA levels
in MCF-7 and MDA-MB-231 cell lines upon miR-21
inhibition, although the increase of EIF4A2 in MDA/
LNA-antimiR-21 cells was relatively modest (Figure 4c).
To determine whether miR-21 affects the expression of
the potential endogenous target genes, we transfected
MCF-7 and MDA-MB-231 cells with LNA-antimiR-21
or LNA-control. Western bolt showed that LNA-anti-
miR-21 led to up-regulation of endogenous ANKRD46
in both MCF-7 (P = 0.005) and MDA-MB-231 cells
(P = 0.004), but no significant up-regulation of EIF4A2
protein (Figure 5c).
We further tested whether miR-21 could directly
repress the identified mRNA targets through 3’ UTR
interactions (Figure 5a). Thus, the full-length 3’ UTRs of
the human genes ANKRD46 and EIF4A2 were cloned
into the downstream of the luciferase gene (pMIR-
REPORT), respectively. These vectors were then used to
assess whether miR-21 could repress luciferase activity
in 293T cells. ANKRD46 3’ UTR showed a reduction to
54.8% of total luciferase reporter activity, in presence of
miR-21,b u tEIF4A2 3’ UTR did not display significant
reduction of luciferase levels, compared with the miR-
control (Figure 5b). These results suggest that miR-21
directly targets ANKRD46 in BC cells.
miR-21 and EIF4A2 proteins are inversely expressed in
resected patient tumors in vivo
We examined ANKRD46 [NCBI: NP940683] and
EIF4A2 [NCBI: NP001958] protein levels by IHC on
TMAs constructed by the BC cases described in
Figure 4 mRNA profiling of miR-21-knockdown BC cell lines. MCF-7 and MDA-MB-231 cells were transfected with 50 nM LNA-antimiR-21 or
LNA-control. Total RNAs were isolated from MCF-7 cells 48 h post transfection and from MDA-MB-231 cells 36 h post transfection, respectively,
and were hybridized to the human genome oligo array V1.0 (CapitalBio, China). (a) The scatter plot shows the LNA-antimiR-21 expression values
normalized to LNA-control values, applying a cut-off of 1.3. Each dot represents one probe set. (b) Unsupervised hierarchical cluster analysis of
intersection of mRNAs differentially expressed in MCF-7 and MDA-MB-231 cells upon LNA-antimiR-21 treatment. Rows, mRNAs; columns,
biological samples. For each mRNA, red is expression higher than average expression across all samples, green is expression lower than average.
(c) Validation of microarray results by qRT-PCR, normalizing on GAPDH RNA levels. MCF/A, MCF/LNA-antimiR-21; MCF/C, MCF/LNA-control; MDA/
A, MDA/LNA-antimiR-21, MDA/C, MDA/LNA-control.
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plasm, and ANKRD46 was seen in both the cytoplasm
and nucleus (Figure 6a). ANKRD46 low expression was
found in 47.5% (staining score < 4; median = 4); EIF4A2
low expression was found in 21.2% (staining score < 7;
median = 7) of the 99 BC cases. Next, we investigated
the negative regulation of endogenous EIF4A2 and
ANKRD46 protein by endogenous miR-21 in vivo.I n9 9
successfully tested cases out of 113, endogenous miR-21
and EIF4A2 protein levels were inversely expressed in
resected patient tumors (rs = -0.283, n =9 9 ,P = 0.005,
Spearman’s correlation analysis). However, no significant
association between miR-21 and ANKRD46 (P =0 . 1 8 1 ,
Spearman’s correlation analysis) was observed.
Table 2 Regulated mRNAs in BC cells after miR-21 knockdown determined by oligo array
Fold change
Gene Name NCBI accession number Genbank
accession
number
Description MCF-7 MDA-
MB-231
Prediction
program
ANKRD46 NM_198401 U79297, BC035087 ankyrin repeat domain 46 1.78 2.57
# miRBase
Targets V5
ACTN4 NM_004924 BC005033 Alpha-actin 4 (F-actin cross linking protein) 1.75 1.55
NR0B1 NM_000475 S74720 Nuclear receptor 0B1 (Nuclear receptor DAX-
1)
1.60 1.32
HIRA NM_003325 BC039835, X89887 HIRA protein 1.48 1.32
COL18A1 NM_030582, NM_130444,
NM_130445
AF018081 Collagen alpha 1(XVIII) chain precursor 1.43 1.35
SAMD11 NM_152486 BC024295,
AK054643
sterile alpha motif domain containing 11 1.42 1.34
EIF4A2 NM_001967 AL117412 Eukaryotic initiation factor 4A-II 1.42 1.41 miRNAMap
SFRS16 NM_007056 AF042800,
AK094681
Splicing factor, arginine/serine-rich 16 1.40 1.34
NP_079316 - BC004930 zinc finger protein 614 1.37 1.36
IL18BP NM_173043, NM_005699,
NM_173042
AF110801 Interleukin-18 binding protein precursor 1.36 1.34
GBF1 NM_004193 AK025330,
AF068755
Golgi-specific brefeldin A-resistance guanine
nucleotide exchange factor 1
1.35 1.51
GNPDA1 NM_005471 AJ002231 Glucosamine-6-phosphate isomerase 1.34 1.32
SPUF_HUMAN NM_013349 - SPUF protein precursor 1.34 1.31
PLXNA1 NM_032242 AK127254 plexin A1; plexin 1 1.32 1.57
STMN3 NM_015894 AK094112 Stathmin 3 (SCG10-like protein) 1.32 1.47
NP_056236 NM_015421 AK093383,
AL080088
DKFZP564K2062 protein 1.31 1.33
- - AK056473 - 1.31 1.30
AP2B1 NM_001282 M34175 adaptor-related protein complex 2, beta 1
subunit
1.31 1.45
HIST1H2AC - CR608156 Histone H2A.l (H2A/l) -1.47 -1.67
PRKCI NM_002740 L33881, BC042405,
BC022016
Protein kinase C, iota type -1.43 -1.32
SLC25A3 NM_002635, NM_213611,
NM_213612, NM_005888
BX647062,
AK057575
Phosphate carrier protein, mitochondrial
precursor (PTP)
-1.39 -1.39
CCNE1 NM_057182, NM_001238 M74093,
BC035498
G1/S-specific cyclin E1 -1.37 -1.39
DCAMKL1 NM_004734 AB002367 Serine/threonine-protein kinase DCAMKL1 -1.34 -1.46
GNG12 NM_018841 AL832431 Guanine nucleotide-binding protein G(I)/G(S)/
G(O) gamma-12 subunit
-1.32 -1.40 Miranda
Q8TAY7 NM_024869 BC025658 hypothetical protein FLJ14050 -1.32 -1.31
NP_653284 NM_144683 BC015582 hypothetical protein MGC23280 -1.31 -1.35
NP_055182 NM_014367 - growth and transformation-dependent
protein
-1.30 -1.34
Fold-regulation of mRNAs affected by miR-21 knockdown compared with control-transfected cells (MCF-7 and MDA-MB-231) at indicated time points. Fold-
changes for all mRNAs are derived from a single microarray experiment, with two relevant genes confirmed by qRT-PCR (Figure 4B). Shown are mRNAs changing
by at least 1.3-fold in both cell lines. Genes in bold were selected for candidate gene analyses by qRT-PCR.;
# marginal signal intensity; NCBI, National Center for
Biotechnology Information; GB, GenBank.
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clinicopathological features and prognosis
Using Pearson’s Chi-Square test, we found that, in BC
tissues, IF4A2 protein correlated with CerbB2 status
(P = 0.019), and ANKRD46 protein correlated with ER
(P = 0.021) and PR (P = 0.001, Table 3). No significant
correlation was observed between EIF4A2, ANKRD46,
or other parameters. The five-year overall survival rate
of the 99 BC patients was 59.60% (Figure 6b). The five-
year survival rate in patients with high EIF4A2 protein
level was 64.10% (n = 78), significantly higher than
those with a low EIF4A2 protein level (42.86%, n =2 1 ;
P = 0.044, log-rank test; Figure 6b). The five-year survi-
val rate in patients with high ANKRD46 protein was
53.85% (n = 52), which was not statistically different
from those with low ANKRD46 protein (65.96%, n = 47;
P = 0.146, log-rank test; Figure 6b).
Discussion
miR-21 is a key molecule in a wide range of cancers,
and identifying its functional role in BC has direct clini-
cal implications. We show here that knockdown of miR-
21 suppresses cell growth and proliferation of MCF-7
cells in vitro, and suppresses MCF-7 xenograft growth.
This result is consistent with the findings of Si et al. [9].
Interestingly, our study suggests that LNA-antimiR-21
also suppresses the growth and proliferation of MDA-
MB-231 in vitro, in contrast to a recent report that
found no effect of LNA-antimiR-21 on the growth of
MDA-MB-231 in vitro or in vivo, although anti-miR-21-
treated tumors were slightly smaller than control tumors
[10]. One possibility could be differences in transfection
efficiency, or miRNA ASO potency. Our results suggest
that, as an oncomir, miR-21 also affects cell migration.
MCF-7 cells are hormone-sensitive and difficult
to culture in vivo. Therefore, we used 17-estradiol to
facilitate MCF-7 cells growth in nude mice, which is a
common technique. Recently, estradiol was shown to
down-regulate miR-21 expression in MCF-7 cells [32],
although another study found estradiol-mediated up-
regulation of miR-21 in MCF-7 cells [33]. In our study,
the miR-21 knockdown effect was reduced from 5.72
log2-scale reduction before cell injection to 0.96 log2-
scale reduction after mice sacrifice. Based on our results,
we propose that estradiol reduced differences in miR-21
level between MCF/PNA-antimiR-21 and MCF/PNA-
control cells, which would explain, in part, why differ-
ences in tumor weight between the two groups were not
significance (P = 0.065). Nonetheless, treatment with
anti-miR-21 reduced MCF-7 xenograft growth by
approximately 68% for up to nine days. In vivo results
suggested that the PNA-based miR-21 inhibitor had a
subtle yet reproducible inhibitory effect on tumor
growth. MCF-7 xenograft tumor sections demonstrated
that miR-21 inhibition induced apoptosis of MCF-7
cells, confirming a previous s t u d y[ 9 ] .W ea l s os h o w e d
that miRNA inhibition can be achieved without trans-
fection or electroporation of human BC cell lines,
Figure 5 ANKRD46 is a direct target of miR-21 in BC cell lines.
(a) Predicted alignment of miR-21 with the target site derived from
ANKRD46 and EIF4A2 3’ UTR, determined with the software miRBase
Targets V5 and miRNAMap, respectively. Note the seed matches at
the 5’ end of miR-21 (grey boxes) and the mutated nucleotides
(underlined). (b) Luciferase assays show that miR-21 directly repress
ANKRD46 mRNAs through 3’ UTR interactions. Part of the 3’ UTRs of
wild-type ANKRD46 (478-bp length) and EIF4A2 (194-bp length), or
the mutations were cloned into pMIR-REPORT vector (Applied
Biosystems), downstream of luciferase. These vectors were then
cotransfected with synthetic miR-21 (pre-miR-21) or miR-control in
293T cells, and luciferase activity was quantified. The graph shows
the percentage of remaining luciferase activity calculated by
normalizing the miR-21 expression values on the miR-control values.
(c) Western blot to assay ANKRD46 and EIF4A2 after miR-21
knockdown, with GAPDH as equal loading control, followed by
densitometric analysis. Cells were treated and harvested as
described in Figure 4b. Data in (b) and (c) are mean + SD (n = 3).
* P < 0.05. WT, wild-type; Mut, mutant.
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applications.
ANKRD46, also known as ankyrin repeat small protein
(ANK-S), is a 228-amino acid single-pass membrane
protein, of unclear function. For the first time, we iden-
tify miR-21 as an important regulator of ANKRD46
mRNA and protein levels in BC cells. Our data showed
that miR-21 directly interacted with the ANKRD46 3’
UTR and inhibited ANKRD46 expression, though there
was no significant association between miR-21 and
ANKRD46 in resected patient tumors. This discrepancy
may be due to three reasons. First, the artificial lucifer-
ase reporter assays do not fully recapitulate miRNA
regulation in vivo [34]; second, the expression of
ANKRD46 protein in patient tumors reflected specific
time-point feature, which maybe different to the in vitro
subsequent increase of ANKRD46 protein at the time
point of observation (the indicated hours after transfec-
tion); third, immunohistochemistry (IHC) is conven-
tional a semi-quantitative method with relatively limited
sensitivity. IHC may not be sensitive enough to observe
the down-regulation of ANKRD46 by miR-21. Functional
Figure 6 EIF4A2 or ANKRD46 expression and survival in BC patients. (a) Representative TMAs sections stained for ANKRD46 and EIF4A2
from different BC. Examples for staining score 0 (negative), 3, 5 and 7 of marker expression are shown. All images were taken at × 200.
(b) Kaplan-Meier survival curve and log-rank test for 99 BC patients showing five-year overall survival. ANKRD46 expression had no significant
relationship to patient survival (P = 0.146). High EIF4A2 expression was associated with significantly improved OS (P = 0.044) in women with BC.
TMAs, tissue microarrays; OS, overall survival.
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weather ANKRD46 is a functional target of miR-21 in BC
progression as demonstrated in this study.
EIF4A2, an ATP-dependent RNA helicase, is expressed
widely in human tissues [35]. In this study, we found that
miR-21 and EIF4A2 protein were inversely expressed in
resected BC patient tumors. But we did not find miR-21
binding sites in the EIF4A2 3’ UTR and found no signifi-
cant increase of EIF4A2 protein upon miR-21 knock-
down in MCF-7 and MDA-MB-231 cells, although
EIF4A2 mRNA increased after anti-miR-21 transfection.
Taken together, the data reported here suggest that there
maybe unknown indirect interactions between miR-21
and EIF4A2 in BC progression. In adult mice, the expres-
sion of the two EIF4A isoforms is dependent on cell
growth status, with EIF4A1 expressed in all tissues, while
EIF4A2 is expressed only in tissues with a low rate of cell
proliferation [36], indicating an anti-proliferative effect
for EIF4A2. We for the first time revealed that low
EIF4A2 expression correlated with low ERBB2 expression
and poor survival of BC patients, suggesting its possible
functional role in BC and urging further investigation.
Conclusions
We demonstrate that MCF-7 and MDA-MB-231 cells
transfected with anti-miR-21 show growth inhibition
in vitro and in vivo,a sw e l la sc e l lm i g r a t i o nin vitro.I n
addition, ANKRD46 is newly identified as a direct target
of miR-21 in BC. These results suggest that miR-21 inhi-
bitory strategies using PNA-antimiR-21 may have poten-
tial for therapeutic applications in BC treatment.
Additional material
Additional file 1: Word document containing the protocol of LNA-
based CISH and FISH for miRNA in the present study.
Additional file 2: Excel file containing a table listing RT and PCR
primers for miR-21 and putative target genes.
Additional file 3: PDF file comprising a figure showing the
expression of miR-21 in human BC tissues and FA tissues by FISH.
Positive in situ hybridization signals are green (FITC). miR-21 expression
levels in BC tissues are much higher than that in corresponding NATs.
Additional file 4: PDF file comprising a figure showing relative miR-
21 induction by LNA-antimiR in BC cells. Relative miR-21 induction in
LNA-antimiR-21 transfected MCF-7 (a) and MDA-MB-231 cells (b). Cells
were transfected either with LNA-antimiR-21 or with LNA-control using
Lipofectamine 2000 (Invitrogen) at indicated doses, and harvested at 12
h, 24 h, 36 h, 48 h, 60 h and 72 h, respectively. Total RNAs were isolated
to quantify miR-21 expression by relative qRT-PCR, normalizing on U6
RNA levels. The graph shows a log2-scale RQ calculated by normalizing
the miR-21 expression values in the LNA-antimiR-21 transfected cells on
that in the LNA-control independently for each time point and dose. 50
nM LNA reagents at 48 h for MCF-7 and 50 nM at 36 h for MDA-MB-231
cells showed the best inhibition effects. Data indicate the mean (+SD) of
three independent transfection experiments.
Table 3 Correlation between target gene protein levels and clinicopathological parameters of 99 BC cases
Variable EIF4A2 ANKRD46
Low (n = 21) High (n = 78) P* Low (n = 47) High (n = 52) P*
Age (years)
< 48 8 39 0.332 23 24 0.782
≥ 48 13 39 24 28
Pathologic grade
I 2 20 0.115 14 10 0.221
II, III 19 58 33 42
Clinical stage**
I, II 15 61 0.514 41 37 0.051
III 6 17 6 15
Lymph node status
Metastasis 14 43 0.342 23 34 0.098
No Metastasis 7 35 24 18
ER status
Negative 12 36 0.371 18 32 0.021
Positive 9 42 29 20
PR status
Negative 11 28 0.170 11 29 0.001
Positive 10 50 36 23
CerbB2 status
0,1+ 17 41 0.019 29 18 0.832
2+,3+ 4 37 31 21
*Two-sided Pearson Chi-Square Test; ** there were no stage IV patients because all the cases selected were surgical patients without neoadjuvant therapy to
avoid the effect of the preoperative radiotherapy and/or chemotherapy on miRNAs; EIF4A2, eukaryotic translation initiation factor 4A2 protein; ANKRD46, ankyrin
repeat domain 46 protein; ER, estrogen receptor; PR, progesterone receptor; CerbB2, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors.
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3’ UTR: 3’ untranslated region; AJCC: American Joint Committee on Cancer;
ANK-S: ankyrin repeat small protein; ASOs: antisense oligonucleotides;
BC: breast cancer; CerbB2: v-erb-b2 erythroblastic leukaemia viral oncogene
homolog 2 receptors; CISH: chromogenic in situ hybridization; DAPI: 4’,6-
diamidino-2-phenylindole; EIF4A2: eukaryotic initiation factor 4A: isoform 2;
ER: estrogen receptor; F: forward primer; FA: fibroadenoma; FISH: fluorescein
in situ hybridization; FITC: fluorescein isothiocyanate; GEO: Gene Expression
Omnibus; IHC: immunohistochemistry; L: length; LNA: Locked nucleic acid;
miRNAs: microRNAs; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; Mut: mutation; NATs: normal adjacent tissues; NBT/BCIP: nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate; NCBI: National Center for
Biotechnology Information; OS: overall survival; PNAs: peptide nucleic acids;
PR: progesterone receptor; qRT-PCR: quantitative reverse transcription-
polymerase chain reaction; R: reverse primer; RQ: relative quantification;
RT: reverse transcription primer; SABC-AP: alkaline phosphatase-conjugated
strept-avidin-biotin complex; SD: standard deviation: SYSUCC: Sun Yat-sen
University Cancer Center; TMAs: tissue microrrays; TNM: tumor-lymph node-
metastasis; W: width; WT: wild-type.
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